Evidence map›Paper›PMID 39659832›Full record

ArticleNeuro-oncology advances

Impact of tumor-treating fields on the survival of Japanese patients with newly diagnosed glioblastoma: A multicenter, retrospective cohort study.

Masayuki Kanamori, Shunsuke Tsuzuki, Ichiyo Shibahara, Kuniaki Saito, Yoshiteru Shimoda, Kazuhiro Tanaka, Shigeru Yamaguchi, Manabu Natsumeda, Tomoo Matsutani, Mitsuto Hanihara and 40 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

50 authors.

Masayuki KanamoriDepartment of Neurosurgery, Tohoku University Graduate School of Medicine, Sendai, Japan.ORCID https://orcid.org/0000-0002-3380-1192
Shunsuke TsuzukiDepartment of Neurosurgery, Tokyo Women's Medical University, Tokyo, Japan.
Ichiyo ShibaharaDepartment of Neurosurgery, Kitasato University School of Medicine, Sagamihara, Japan.
Kuniaki SaitoDepartment of Neurosurgery, Kyorin University Facility of Medicine, Tokyo, Japan.
Yoshiteru ShimodaDepartment of Neurosurgery, Tohoku University Graduate School of Medicine, Sendai, Japan.
Kazuhiro TanakaDepartment of Neurosurgery, Kobe University Graduate School of Medicine, Kobe, Japan.
Shigeru YamaguchiDepartment of Neurosurgery, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Manabu NatsumedaDepartment of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Japan.ORCID https://orcid.org/0000-0003-3098-8323
Tomoo MatsutaniDepartment of Neurological Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
Mitsuto HaniharaDepartment of Neurosurgery, University of Yamanashi, Yamanashi, Japan.
Mitsutoshi NakadaDepartment of Neurosurgery, Kanazawa University, Kanazawa, Japan.
Jun-Ichiro KurodaDepartment of Neurosurgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Masahide MatsudaDepartment of Neurosurgery, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
Koji YoshimotoDepartment of Neurosurgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Ushio YonezawaDepartment of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Yukihiko SonodaDepartment of Neurosurgery, Faculty of Medicine, Yamagata University, Yamagata, Japan.
Koji TakanoDepartment of Neurosurgery, Osaka International Cancer Institute, Osaka, Japan.
Hajime YonezawaDepartment of Neurosurgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.ORCID https://orcid.org/0000-0003-3144-992X
Yoshihiro OtaniDepartment of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Yukiko NakaharaDepartment of Neurosurgery, Faculty of Medicine, Saga University, Saga, Japan.
Masashi UchidaDepartment of Neurosurgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.
Masahiro NonakaDepartment of Neurosurgery, Kansai Medical University, Hirakata, Japan.
Yohei MineharuDepartment of Neurosurgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Yohei KitamuraDepartment of Neurosurgery, Keio University School of Medicine, Tokyo, Japan.
Shinji YamashitaDivision of Neurosurgery, Department of Clinical Neuroscience, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Takahiro YamauchiDivision of Medicine, Department of Neurosurgery, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Yohei MiyakeDepartment of Neurosurgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Shoichi DeguchiDivision of Neurosurgery, Shizuoka Cancer Center, Nagaizumi, Japan.ORCID https://orcid.org/0000-0003-2424-2314
Takaaki BeppuDepartment of Neurosurgery, Iwate Medical University, Shiwa, Japan.
Kaoru TamuraDepartment of Neurosurgery, Tokyo Medical and Dental University, Tokyo, Japan.
Shinichiro KoizumiDepartment of Neurosurgery, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Yuichi HiroseDepartment of Neurosurgery, Fujita Health University, Toyoake, Japan.
Kenichiro AsanoDepartment of Neurosurgery, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Ryo HirutaDepartment of Neurosurgery, Fukushima Medical University, Fukushima, Japan.
Manabu KinoshitaDepartment of Neurosurgery, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.
Keisuke MiyakeDepartment of Neurological Surgery, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Noriyuki NakayamaDepartment of Neurosurgery, Graduate School of Medicine, Gifu University, Gifu, Japan.
Akihiro InoueDepartment of Neurosurgery, Ehime University School of Medicine, Toon, Japan.
Takahiro OnoDepartment of Neurosurgery, Akita University Graduate School of Medicine, Akita, Japan.
Takahiro SasakiDepartment of Neurological Surgery, School of Medicine, Wakayama Medical University, Wakayama, Japan.
Yukinori AkiyamaDepartment of Neurosurgery, Sapporo Medical University, Sapporo, Japan.
Shinjiro FukamiDepartment of Neurosurgery, Tokyo Medical University, Tokyo, Japan.
Atsuo YoshinoDepartment of Neurological Surgery, Nihon University School of Medicine, Tokyo, Japan.
Yu KawanishiDepartment of Neurosurgery, Kochi Medical School, Kochi University, Kochi, Japan.
Taku AsanomeDepartment of Neurosurgery, Brain Tumor Center, Nakamura Memorial Hospital, Sapporo, Japan.
Takuhiro YamaguchiDivision of Biostatistics, Tohoku University Graduate School of Medicine, Sendai, Japan.
Masamichi TakahashiDepartment of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tokyo, Japan.
Fumiyuki YamasakiDepartment of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.ORCID https://orcid.org/0000-0003-0164-6295
Yoshiki ArakawaDepartment of Neurosurgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID https://orcid.org/0000-0003-4626-4645
Yoshitaka NaritaDepartment of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tokyo, Japan.ORCID https://orcid.org/0000-0003-4303-6006

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The EF-14 clinical trial demonstrated the safety and efficacy of tumor-treating fields (TTFields) for newly diagnosed glioblastoma. This study aimed to clarify the current status, safety, and efficacy of TTFields in Japanese patients who meet the EF-14 inclusion criteria. Methods: This was a multicenter retrospective cohort study. Background, treatment, and outcome data of patients who satisfied the inclusion criteria of the EF-14 trial were collected from 45 institutions across Japan. The rate, determinants, and current status of TTField use, including its safety and efficacy in terms of progression and survival, were retrospectively investigated. This study was conducted in accordance with the STROBE checklist. Results: Among the 607 patients enrolled, 70 were excluded due to progressive disease during radiation and temozolomide therapy, age > 80 years old, and Karnofsky Performance Status score of <70. Among the remaining 537 patients, 210 (39%) underwent TTField treatment. Multivariate analysis revealed younger age and spouse as a caregiver as significant factors for TTField use. The compliance rate of TTField use exceeded 75% in 60% of patients, with a median TTField usage duration of 11 months. Skin disorders requiring medical treatment occurred in 56% of patients. Multivariate Cox proportional hazards analysis in the whole series and propensity score-matched analysis revealed that TTField use was not a prognostic factor for progression-free survival (PFS) or overall survival (OS). Conclusions: TTField use did not have a substantial effect on either PFS or OS in Japanese patients with glioblastoma, despite compliance rates comparable to those observed in the EF-14.

Indexed as

Asian populationdeterminant of useglioblastomasurvivaltumor-treating fields

Identifiers

PMID39659832
PMCPMC11629686

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.